Avidity Biosciences Inc (NASDAQ: RNA) is 1.62% higher on its value in year-to-date trading and has touched a low of $18.56 and a high of $56.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RNA stock was last observed hovering at around $28.56 in the last trading session, with the day’s gains setting it 0.99%.
Currently trading at $29.55, the stock is -6.77% and -4.62% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.57 million and changing 3.47% at the moment leaves the stock -23.52% off its SMA200. RNA registered 46.94% gain for a year compared to 6-month loss of -32.84%.
The stock witnessed a -7.54% gain in the last 1 month and extending the period to 3 months gives it a -31.33%, and is -0.34% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.10% over the week and 5.63% over the month.
Avidity Biosciences Inc (RNA) has around 391 employees, a market worth around $3.55B and $10.90M in sales. Profit margin for the company is -2957.72%. Distance from 52-week low is 59.21% and -47.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-22.57%).
with sales reaching $2.44M over the same period.The EPS is expected to shrink by -38.89% this year, but quarterly earnings will post -25.15% year-over-year. Quarterly sales are estimated to shrink -31.25% in year-over-year returns.
The shares outstanding are 119.89M, and float is at 111.07M with Short Float at 14.84%.
The top institutional shareholder in the company is FMR LLC with over 16.16 million shares valued at $660.1 million. The investor’s holdings represent 18.5285 of the RNA Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 10.92 million shares valued at $445.94 million to account for 12.5173 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 8.62 million shares representing 9.8868 and valued at over $352.23 million, while RTW INVESTMENTS, LP holds 8.2362 of the shares totaling 8.81 million with a market value of $359.76 million.
Avidity Biosciences Inc (RNA) Insider Activity
A total of 0 insider transactions have happened at Avidity Biosciences Inc (RNA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Gallagher Kathleen P., the company’s Chief Program Officer. SEC filings show that Gallagher Kathleen P. sold 5,875 shares of the company’s common stock on Mar 03 ’25 at a price of $29.41 per share for a total of $0.17 million. Following the sale, the insider now owns 50554.0 shares.
Avidity Biosciences Inc disclosed in a document filed with the SEC on Feb 03 ’25 that Gallagher Kathleen P. (Chief Program Officer) sold a total of 5,875 shares of the company’s common stock. The trade occurred on Feb 03 ’25 and was made at $32.16 per share for $0.19 million. Following the transaction, the insider now directly holds 50554.0 shares of the RNA stock.
Still, SEC filings show that on Feb 03 ’25, KATHLEEN GALLAGHER (Officer) Proposed Sale 17,625 shares at an average price of $32.93 for $0.58 million. The insider now directly holds shares of Avidity Biosciences Inc (RNA).
Avidity Biosciences Inc (RNA): Who are the competitors?
One of the company’s main competitors (and peers) include Vertex Pharmaceuticals Inc. (VRTX) that is trading 19.37% up over the past 12 months.GSK PLC ADR (GSK) lies in the list of competitors of the Avidity Biosciences Inc and is -8.94% lower over the same period from RNASarepta Therapeutics Inc. (SRPT) is -10.51% down on the 1-year trading charts.
